Max Robotics — Global Service Robot Directory + US Certification

About

Joshua Myers is a pioneering biomedical researcher at the forefront of oral biologic drug delivery, with a focus on robotic pill technologies that transform the administration of large-molecule therapeutics. His major contributions center on developing and clinically validating an orally ingestible robotic pill capable of safely delivering complex drugs—including teriparatide for osteoporosis, an ustekinumab biosimilar for inflammatory conditions, and a follicle-stimulating hormone biosimilar for reproductive health—with bioavailability comparable to subcutaneous injections. In his most-cited 2025 phase 1 study (3 citations), Myers demonstrated that this robotic pill achieves reliable, high bioavailability of teriparatide, addressing a critical need for the projected 70 million osteoporosis patients over 65 by 2030. His 2024 work (2 citations) further showed successful delivery of an ustekinumab biosimilar, while his 2023 proof-of-concept study (2 citations) highlighted patient preference for a once-daily oral FSH biosimilar. Myers’ research promises to revolutionize chronic disease management by eliminating needle-based injections, improving patient adherence, and expanding access to biologic therapies. His work at Rani Therapeutics underscores a commitment to translating innovative engineering into practical, patient-friendly solutions.